Biotricity, Inc.

  • Market Cap: Micro Cap
  • Industry: Software Products
  • ISIN: US09074H2031
USD
0.28
-0.22 (-44.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

22.18 k

Shareholding (Sep 2025)

FII

0.04%

Held by 3 FIIs

DII

98.76%

Held by 1 DIIs

Promoter

0.00%

How big is Biotricity, Inc.?

22-Jun-2025

As of Jun 18, Biotricity, Inc. has a market capitalization of 11.96 million, with net sales of 13.27 million and a net profit of -10.66 million over the last four quarters. The company has shareholder's funds of -29.98 million and total assets of 5.94 million as of Mar 24.

Market Cap: As of Jun 18, Biotricity, Inc. has a market capitalization of 11.96 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Biotricity, Inc. reported net sales of 13.27 million and a net profit of -10.66 million.<BR><BR>Balance Sheet Snapshot: As of the latest reporting period in Mar 24, the company has shareholder's funds of -29.98 million and total assets amounting to 5.94 million.

View full answer

What does Biotricity, Inc. do?

22-Jun-2025

Biotricity, Inc. is a micro-cap company in the Software Products industry, reporting net sales of $4 million and a net loss of $1 million as of December 2024. It has a market cap of $11.96 million and key metrics indicating a loss-making status with a return on equity of 34.59%.

Overview: <BR>Biotricity, Inc. operates in the Software Products industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 4 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 11.96 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.82 <BR>Return on Equity: 34.59% <BR>Price to Book: -0.40<BR><BR>Contact Details: <BR>Registrar Address: Not available.

View full answer

Should I buy, sell or hold Biotricity, Inc.?

22-Jun-2025

Is Biotricity, Inc. overvalued or undervalued?

20-Sep-2025

As of February 14, 2020, Biotricity, Inc. is considered a risky investment due to its overvaluation and significant financial distress, reflected in negative valuation metrics and a volatile stock performance, despite a recent year-to-date return of 114.87%.

As of 14 February 2020, the valuation grade for Biotricity, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued, as evidenced by a Price to Book Value of -0.44 and an EV to EBITDA ratio of -8.26, both of which suggest significant financial distress. Additionally, the company's P/E ratio is not applicable due to it being loss-making, further complicating its valuation.<BR><BR>In comparison to its peers, Biotricity's valuation metrics are concerning; for instance, CareCloud, Inc. has a P/E of 12.655, while Biotricity's is -3.7032, highlighting a stark contrast in financial health. Other risky peers like Intellinetics, Inc. and Zenvia, Inc. also show negative valuations, with EV to EBITDA ratios of -49.2573 and 4.5867, respectively. Notably, Biotricity's recent stock performance has been volatile, with a YTD return of 114.87% compared to the S&P 500's 12.22%, yet this is overshadowed by a 3Y return of -90.97%, indicating long-term challenges.

View full answer

Is Biotricity, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Biotricity, Inc. shows a bullish trend with a year-to-date return of 114.87%, significantly outperforming the S&P 500, despite mixed signals from some technical indicators and long-term underperformance.

As of 2 September 2025, the technical trend for Biotricity, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by a bullish daily moving average. The KST is also bullish on a weekly basis, while the monthly indicators show a mildly bullish stance. However, the RSI shows no signal on both weekly and monthly time frames. The Bollinger Bands indicate a mildly bullish trend weekly but are sideways monthly. Overall, the Dow Theory shows no trend weekly and mildly bullish monthly.<BR><BR>In terms of performance, Biotricity has a year-to-date return of 114.87%, significantly outperforming the S&P 500's 12.22% during the same period. However, over longer periods, the stock has underperformed, with a 3-year return of -90.97% compared to the S&P 500's 70.41%. <BR><BR>The current stance is bullish, with moderate strength indicated by the weekly MACD and moving averages, despite some mixed signals from other indicators.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate 13.84% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -3.00
2

Risky - Negative EBITDA

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Software Products

stock-summary
Market cap

USD 8 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

14.03%

stock-summary
Price to Book

-0.25

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.76%
0%
-48.76%
6 Months
2.37%
0%
2.37%
1 Year
-71.77%
0%
-71.77%
2 Years
-93.31%
0%
-93.31%
3 Years
-96.16%
0%
-96.16%
4 Years
-98.8%
0%
-98.8%
5 Years
-96.97%
0%
-96.97%

Biotricity, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
56.51%
EBIT Growth (5y)
13.84%
EBIT to Interest (avg)
-3.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
-2.47
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.71%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.44
EV to EBIT
-8.08
EV to EBITDA
-8.26
EV to Capital Employed
-6.96
EV to Sales
2.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.19%)

Foreign Institutions

Held by 3 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 21.88% vs 6.67% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 81.08% vs -8.82% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.90",
          "val2": "3.20",
          "chgp": "21.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "-1.10",
          "chgp": "127.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.90",
          "chgp": "-47.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-3.70",
          "chgp": "81.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "72.80%",
          "val2": "-348.80%",
          "chgp": "42.16%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 14.05% vs 26.04% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 40.43% vs 24.60% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.80",
          "val2": "12.10",
          "chgp": "14.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-8.50",
          "chgp": "76.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.20",
          "val2": "5.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.40",
          "val2": "-14.10",
          "chgp": "40.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-177.60%",
          "val2": "-731.80%",
          "chgp": "55.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
3.90
3.20
21.88%
Operating Profit (PBDIT) excl Other Income
0.30
-1.10
127.27%
Interest
1.00
1.90
-47.37%
Exceptional Items
-0.00
-0.40
100.00%
Consolidate Net Profit
-0.70
-3.70
81.08%
Operating Profit Margin (Excl OI)
72.80%
-348.80%
42.16%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 21.88% vs 6.67% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 81.08% vs -8.82% in Jun 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
13.80
12.10
14.05%
Operating Profit (PBDIT) excl Other Income
-2.00
-8.50
76.47%
Interest
5.20
5.20
Exceptional Items
-0.70
0.00
Consolidate Net Profit
-8.40
-14.10
40.43%
Operating Profit Margin (Excl OI)
-177.60%
-731.80%
55.42%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 14.05% vs 26.04% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 40.43% vs 24.60% in Mar 2024

stock-summaryCompany CV
About Biotricity, Inc. stock-summary
stock-summary
Biotricity, Inc.
Software Products
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available